Alliance Global Partners initiated coverage of Chromocell Therapeutics with a Buy rating and $8.50 price target. Chromocell’s pipeline includes two lead non-opioid pain-alleviating candidates, CC8464 and CT2000, and the firm’s sum-of-the-parts analysis values CT2000 at $5 per share, CC8464 for idiopathic small fiber neuropathy, or ISFN, at $1.50 per share, and the company’s remaining compounds, underlying technology and cash at $2 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRO:
Questions or Comments about the article? Write to editor@tipranks.com